Pharmaceuticals News and Research

RSS

Phase 1 clinical study of ISIS-SOD1Rx in patients with Lou Gehrig's disease commenced

Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 study of ISIS-SOD1Rx in patients with an inherited, aggressive form of Lou Gehrig's disease also known as familial amyotrophic lateral sclerosis (ALS).

5 Mar 2010

Bristol-Myers Squibb to review key accomplishments at meeting with investment community

During a meeting with the investment community today, Bristol-Myers Squibb Company will provide a comprehensive business overview, highlight positive pipeline developments and provide 2013 minimum non-GAAP earnings per share guidance.

5 Mar 2010

China Pharma Holdings reports 21% increase in 2009 revenue

China Pharma Holdings, Inc., which develops, manufactures, and markets specialty pharmaceutical products in China, today announced financial results for the fiscal year ended December 31, 2009.

5 Mar 2010

Cymetrix Board Member Joe Sullivan recognized as 2010 Director of the Year Honoree

Cymetrix Board Member Joe Sullivan was recognized by the Forum for Corporate Directors as a 2010 Director of the Year Honoree. He was recognized in the category of Corporate Growth and Development for playing a significant role in enhancing the growth and operations of the companies he serves.

5 Mar 2010

Glencoe Enterprise article highlights medical innovation and research enable people to live longer, healthier

An article in the Glencoe Enterprise recently highlighted the fact that medical innovation and research are enabling many people to live longer, healthier and more productive lives.

5 Mar 2010

Gene involved in susceptibility and resistance to TB identified

University of Washington researchers have identified a gene involved in susceptibility and resistance to tuberculosis. This same gene, they have found, has a role in the severity of leprosy, which is caused by a related pathogen. The researchers also have learned why this gene is important for susceptibility.

5 Mar 2010

Forteo to remain Decision Resources' proprietary clinical gold standard for treatment of osteoporosis

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a drug's effect on reduction of new hip fractures is the attribute that most influences U.S. and European surveyed primary care physicians' (PCPs') prescribing decisions in osteoporosis.

5 Mar 2010

RMEI, PIM jointly sponsor virtual lecture to address the need for education on ALL in AYAs

Currently, no definitive standard of care exists for adolescent and young adults (AYA) with acute lymphoblastic leukemia (ALL). Recent research suggests that AYAs treated with pediatric treatment protocols have better outcomes than those treated with adult treatment protocols.

5 Mar 2010

KAPIDEX to be marketed as DEXILANT in the U.S.

Takeda Pharmaceuticals North America, Inc. announced today that KAPIDEX™ (dexlansoprazole) will be marketed in the United States under the new product trade name DEXILANT™ (dexlansoprazole). The product is indicated for heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE.

5 Mar 2010

FDA's 5-year NCE exclusivity grant to VYVANSE: Court upholds decision

Shire plc, the global specialty biopharmaceutical company, announces that the United States District Court for the District of Columbia ("Court"), following extensive briefing by the parties and an oral hearing, has upheld the decision of the U.S. Food and Drug Administration ("FDA") to grant 5-year New Chemical Entity ("NCE") exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).

5 Mar 2010

Data evaluating safety, efficacy of STELARA and REMICADE in patients with plaque psoriasis to be presented

Data evaluating the efficacy and safety of STELARA™ (ustekinumab) and REMICADE® (infliximab) in patients with plaque psoriasis who had an inadequate response to Enbrel® (etanercept) will be presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) in Miami, Fla., from March 5-9, 2010.

5 Mar 2010

GSK's Japanese subsidiary begins voluntary recall of Poligrip products containing zinc

Today, the Japanese subsidiary of pharmaceutical giant, GlaxoSmithKline (GSK), announced that it would begin a voluntary recall of Poligrip products that contain zinc in that country Friday. The company's decision followed just three reports of adverse health effects in consumers of the product, sold in Japan as Poligrip EX.

5 Mar 2010

Anthera Pharmaceuticals completes initial public offering at $7.00 per share

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced the completion of its initial public offering of six million shares of common stock at a price of $7.00 per share. The net proceeds of the offering to Anthera, after deducting underwriting discounts and commissions and estimated offering expenses payable by Anthera, were approximately $36.7 million.

5 Mar 2010

Heartburn drug Kapidex to be marketed under new name Dexilant

The U.S. Food and Drug Administration has approved a name change for the heartburn drug Kapidex (dexlansoprazole) to avoid confusion with two other medications – Casodex and Kadian. Effective in late April 2010, Takeda Pharmaceuticals North America Inc. will market Kapidex under the new name Dexilant.

4 Mar 2010

Columbia Laboratories to sell progesterone related assets and 11.2M shares to Watson Pharmaceuticals

Columbia Laboratories, Inc. has entered into a definitive agreement to sell substantially all of its progesterone related assets and 11.2 million shares of common stock to Watson Pharmaceuticals, Inc. for a $47 million upfront payment plus royalties of 10 to 20 percent of annual net sales of certain progesterone products. Additional payments up to $45.5 million can be earned by the successful completion of clinical development milestones in the ongoing PREGNANT Study, regulatory filings, receipt of regulatory approvals and product launches.

4 Mar 2010

Chay Enterprises merges with DMI Life Sciences to form Ampio Pharmaceuticals

Chay Enterprises, Inc. is pleased to announce today that the company has merged with DMI Life Sciences, Inc to form Ampio Pharmaceuticals, Inc. Ampio Pharmaceuticals will trade on the NASDAQ BB under the symbol CHYE. "We have asked FINRA to change our symbol," said Don Wingerter, Ampio Pharmaceuticals' CEO, "and expect to be trading under our new symbol in less than thirty days."

4 Mar 2010

Evaluating bone defect repairs using human stem cells: NeoStem, University of Michigan enter into SRA

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that it has entered into a sponsored research agreement (SRA) with the University of Michigan to evaluate bone defect repairs using human stem cells. The one-year project, beginning in March, will be funded through the proceeds of a $108,746 grant from the National Institutes of Health (NIH) under the Small Business Innovative Research Program (SBIR).

4 Mar 2010

BioSante Pharmaceuticals enters into securities purchase agreements with Great Point and Deerfield Management

BioSante Pharmaceuticals, Inc. today announced that it has received commitments from two institutional investors to purchase $18 million of securities in a registered direct offering. The investors are Great Point Partners, LLC and Deerfield Management Company. BioSante expects to receive net proceeds of approximately $17.5 million after deducting placement agent fees and other offering expenses.

4 Mar 2010

AB SCIEX collaborates with Mass Spectrometry Centre to improve drug discovery and development

AB SCIEX, a global leader in life science analytical technologies, today announced that it is collaborating with the University of Geneva’s Mass Spectrometry Centre to create new workflows and analytical strategies intended to significantly improve drug discovery and development.

4 Mar 2010

Watson Pharmaceuticals to acquire U.S. rights to Columbia's bioadhesive progesterone gel products

Watson Pharmaceuticals, Inc. today announced an agreement to expand their Women's Health brand product portfolio with the acquisition of the exclusive U.S. rights to Columbia Laboratories, Inc.'s bioadhesive progesterone gel products currently marketed under the trade names CRINONE® and PROCHIEVE® for the indications of infertility and secondary amenorrhea.

4 Mar 2010

Pharmaceuticals News and Research

Phase 1 clinical study of ISIS-SOD1Rx in patients with Lou Gehrig's disease commenced

Bristol-Myers Squibb to review key accomplishments at meeting with investment community

China Pharma Holdings reports 21% increase in 2009 revenue

Cymetrix Board Member Joe Sullivan recognized as 2010 Director of the Year Honoree

Glencoe Enterprise article highlights medical innovation and research enable people to live longer, healthier

Gene involved in susceptibility and resistance to TB identified

Forteo to remain Decision Resources' proprietary clinical gold standard for treatment of osteoporosis

RMEI, PIM jointly sponsor virtual lecture to address the need for education on ALL in AYAs

KAPIDEX to be marketed as DEXILANT in the U.S.

FDA's 5-year NCE exclusivity grant to VYVANSE: Court upholds decision

Data evaluating safety, efficacy of STELARA and REMICADE in patients with plaque psoriasis to be presented

GSK's Japanese subsidiary begins voluntary recall of Poligrip products containing zinc

Anthera Pharmaceuticals completes initial public offering at $7.00 per share

Heartburn drug Kapidex to be marketed under new name Dexilant

Columbia Laboratories to sell progesterone related assets and 11.2M shares to Watson Pharmaceuticals

Chay Enterprises merges with DMI Life Sciences to form Ampio Pharmaceuticals

Evaluating bone defect repairs using human stem cells: NeoStem, University of Michigan enter into SRA

BioSante Pharmaceuticals enters into securities purchase agreements with Great Point and Deerfield Management

AB SCIEX collaborates with Mass Spectrometry Centre to improve drug discovery and development

Watson Pharmaceuticals to acquire U.S. rights to Columbia's bioadhesive progesterone gel products

Event guide: World ADC San Diego eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring